Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial

Amanda Vrselja, Susan R. Davis, Rod Baber et al.|The Lancet|2022

Cited by 16